Forte Biosciences, Inc.FBRX

Forte Biosciences (FBRX) shares lurched higher on July 27 after the company announced an acquisition agreement with Belgian biotech argenx, which plans to add Forte’s anti-CD122 antibody FB102 to its immunology pipeline. The deal, disclosed in a trio of SEC filings, comes as Forte reported continued heavy losses: a $22.1M net loss and $18.8M cash burn in Q1 2026, with no revenue to offset the red ink (source: SEC EDGAR 10-Q, period ending 2026-03-31).

Forte’s business model hinges on FB102, a monoclonal antibody targeting inflammatory diseases, though the drug remains in clinical trials with no approved product generating sales. The company’s balance sheet shows $58.2M in cash but $25.1M in liabilities, raising questions about how long it can sustain operations without the argenx lifeline. Meanwhile, a proposed $150M public offering filed the same day as the acquisition announcement suggests Forte is playing both sides of the street-selling shares while negotiating a takeover (source: SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm).

The SEC filings reveal a management desks sprint to close the argenx deal before financial realities catch up. Insiders have filed multiple SC14D-9 disclosures outlining the transaction’s terms, which include stock consideration for Forte shareholders. Yet with no revenue, zero capex, and a cash runway that’s shrinking faster than a wool sweater in a hot wash, the real question is whether argenx is getting a biotech gem or a financial black hole (source: SEC EDGAR SC TO-C, https://www.sec.gov/Archives/edgar/data/1419041/000110465926087141/tm2621326d2_sctoc.htm).